Kimberlin, who previously collaborated with Dr. Jonas Salk to develop the first FDA-approved cell-based immunotherapy, ...
在细胞治疗的研究浪潮中,间充质基质细胞(MSCs)是关键的研究对象。但患者年龄及细胞获取困难等问题制约其临床应用。近日,发表在 Life Sci 的一项研究 iPSC-derived mesenchymal stromal cells ...
China's top drug regulator has recently approved the nation's first stem cell therapy to treat a type of complication ...
Mesenchymal Stromal Cell Therapy is under clinical development by Orbsen Therapeutics and currently in Phase II for Primary Sclerosing Cholangitis.
Dec. 18, 2024 /PRNewswire/ -- Today, the U.S. Food and Drug Administration approved Ryoncil (remestemcel-L-rknd), an allogeneic (donor) bone marrow-derived mesenchymal stromal cell (MSC ...
China's top drug regulator has recently approved the nation's first stem cell therapy to treat a type of complication ...
A Key Milestone for Therapeutic Exosome ProductionTORONTO and HAIFA, Israel, Jan. 08, 2025 (GLOBE NEWSWIRE) -- . (TSXV: NRX), (OTCQB: NRXBF), (Germany: J90) ("NurExone" or the "Company"), a developer ...
In this study, the researchers showed that EVs from fat-derived mesenchymal stromal cells (ASC-EVs) decreased the harmful effects of senescent cells. ASC-EVs showed strong therapeutic effects in ...
an allogeneic bone marrow-derived mesenchymal stromal cell therapy, in pediatric patients with SR-aGvHD categorized as Grade B or D, excluding Grade B skin, assessed by the International Blood and ...